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Slobectomy versus open lobectomy for early stage lung can-
cer are similar. There was no difference in overall survival,
disease-free survival, or survival based on pattern of recur-
rence. There was no difference in time to locoregional
recurrence between the VATS and open lobectomy groups.
Based on the given data, the conclusion that VATS provides
local control at least equivalent to that provided by thoracot-
omy is validated. Concern has been raised that VATS lobec-
tomy for clinical T1-2 N0 NSCLC may lead to less
complete N1 lymph node evaluation and lower rates of
N1 upstaging compared with open lobectomy. Such detec-
tion of nodal involvement may extend the potential benefits
of adjuvant chemotherapy to patients who otherwise would
be offered none. The results of this study are unable to
address this concern because the rate of pN1 involvement
was low in both VATS and open lobectomy groups (8%
and 12%, respectively; P ¼ .49).
In the past, those who doubted the validity of the VATS
lobectomy approach raised concerns that small lung lesions
representative of synchronous primary tumors or metastatic
disease may miss the opportunity for detection by bimanual
palpation at the time of initial operation. This study shows
that the numbers of patients who develop second primary
tumors are not different between the VATS and open lobec-
tomy approach. This finding is in agreement with the con-
clusions of a recent single-institution study that showed
similar incidence of second primary tumors following
lobectomy by VATS versus open technique.10
The limitations of this study include the fact that positron
emission tomography/computed tomography was not
required for entry into the trial; thus clinical staging by
this means was not uniformly used. Data collected in
follow-up was limited by return of data forms by the partici-
pating institutions. VATS sample size for the propensity-
matched analysis was limited. At the time that the trial
was conducted, adjuvant chemotherapy was not the stan-
dard of care for node-positive disease or tumors of size 4
cm or larger.11 These nonetheless do not undermine the
relevance of the reported outcomes in patients undergoing
surgical resection with early stage NSCLC.CONCLUSIONS
As nonsurgical treatments are more commonly used in
treatment of early stage NSCLC, a critical evaluation of
outcomes should be performed. The survival data and recur-
rence patterns following surgical treatment of clinical T1 and
T2 lung cancers in the Z0030 cohort serve as benchmarks
against which the outcomes of ablative techniques such as
stereotactic body radiation therapy must be compared.References
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Dr Scott J. Swanson (Boston, Mass). Dr Su, that was an excel-
lent presentation, and you showed extreme poise while you were
waiting for your slides.
What is your message? Is it that we should pursue more mini-
mally invasive strategies or their equivalent? I think I understand
what you were getting at, but do you have a conclusion from
what you presented here?
Dr Su. Thank you for your question and kind comments,
Dr Swanson. There are several messages one can take from these
data. Themain one is that these data are issued from the largest ran-
domized trial in the U.S. of surgical treatment for early-stage lung
cancer. In terms of recurrence rates and survival, they represent a
benchmark against which nonsurgical therapies (such as stereotac-
tic body radiation therapy [SBRT] or radio-frequency ablation)
must be compared. Additionally, these data provide continued sup-
port for the use of minimally invasive surgery as compared with
open surgery in that recurrence rates, freedom from second pri-
maries, and long-term survival of matched, early-stage lung cancer
patients were similar regardless of surgical approach.
Dr Swanson. I have 1 further question. What do you make out
of articles we have heard about recently about lymph node dissec-
tion or sampling or removal with video-assisted thoracoscopic sur-
gery (VATS) versus open? It seems like your data show anery c February 2014
Su et al General Thoracic Surgeryequivalent ability to get local and locoregional control. Is the cor-
rect conclusion that a VATS approach is equally good to getting
local and regional control—meaning getting out lymph nodes—
for early stage lung cancer? Am I understanding that correctly?
Dr Su. The VATS versus open lobectomy question is relevant
because VATS has been suggested to have a lower risk profile,
and the benefits of SBRT lie in its noninvasiveness and minimal
risks. With regard to the lymph node dissection, only 7% of Z30
trial patients underwent VATS lobectomy. So these data are as
good as it gets in terms of offering best outcomes, because most
of the patients underwent open lobectomy.
DrM.BlairMarshall (Washington,DC). I just have a comment.
I would like to commend Stacey for taking this on. The stereotactic
body radiation literature often compares resultswith old surgical re-
sults, not current data. It is important to continually update our re-
sults. There is too much variability in the literature and the
definition of a local recurrence is variable in much of the stereotac-
tic radiation literature. Those patientswho aremedically inoperable
may never be sent for a biopsy of their recurrence. We have had no
rigorous analysis of the data or outcomes in these studies. It is
important to participate in these trials and have adequate follow-
up of our patients. With the reports currently in the literature, and
the very short-term outcomes being reported, radiation may seem
like an equivalent alternative to surgery. However I am fairly certain
that longer-term data will show that not to be the case.
Dr Raphael Bueno (Boston, Mass). Stacey, that was a great
presentation.
Because you had a large number of patients and they are very
much annotated, is it possible for you to look at those who areThe Journal of Thoracic and Caolder, are the most frail, with the worst pulmonary function and
additional comorbidities? Looking at the data for T1 is not going
to make 90% much worse, but it will be potentially more compa-
rable, and we can show that even in that population we do better. Is
that something you can do?
Dr Su. Sure, that can be looked at. The Z30 trial was essentially
looking at mediastinal nodal sampling versus dissection and the
groups were randomized according to those criteria, but certainly
that is something that can be looked into.
Dr David J. Sugarbaker (Boston, Mass). Very nice presenta-
tion, Dr Su. I have just a question about preoperative staging,
particularly in the T2 lesions. Was there any systematic review
as to which patients would have preoperative endobronchial ultra-
sound or mediastinoscopy?
Dr Su. The Z30 trial required patients to be nodenegative from
the standpoint of N2 nodes and hilar N1 nodes. These patients were
staged according to mediastinoscopy in addition to VATS and tho-
racotomy. Endobronchial ultrasound was not utilized during the
time period of the study.
Dr Sugarbaker. How about positron emission tomography
scans?
Dr Su. Positron emission tomography scans were not consis-
tently used. The study was conducted before those scans were
widely available.
Dr Bueno. But you looked at all T1s regardless of what the
N status was to mimic what the SBRT people might be doing?
Dr Su. SBRT data is often quoted in terms of T1 and T2.
Dr Bueno. So some of your T1s were stage II, potentially?
Dr Su. These were pathologic T1 and pathologic T2 data.rdiovascular Surgery c Volume 147, Number 2 753
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